-
Mashup Score: 0
Minimal Residual Disease (MRD) is one of the big topics in myeloma. Different techniques to measure MRD and new data about its role in predicting the risk of relapse are some of the topics discussed during the American Society of Hematology (ASH) Annual Meeting. In this video Dr Francesca Gay, University of Torino, Italy, explains …
Source: Myeloma Patients EuropeCategories: UncategorizedTweet
-
Mashup Score: 0Real World Evidence at ASH 2019 - Myeloma Patients Europe - 5 year(s) ago
Real World Evidence (RWE) is becoming more and more important not only for clinicians but also for scientific meetings such as the American Society of Hematology (ASH) Annual Meeting. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important updates regarding Real World Evidence in myeloma presented at …
Source: Myeloma Patients EuropeCategories: UncategorizedTweet
-
Mashup Score: 2Bispecific antibodies at ASH 2019 - Myeloma Patients Europe - 5 year(s) ago
Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, …
Source: Myeloma Patients EuropeCategories: UncategorizedTweet
ASH 2019 updates on Minimal Residual Disease (MRD) - Myeloma Patients Europe https://t.co/FXpBgiuv0J